Ä¢¹½ÊÓƵAPP

Kyle Chiang is an Origination Partner at Ä¢¹½ÊÓƵAPP where he leads a team of entrepreneurs responsible for originating and growing new companies. Since joining Flagship, Kyle has held numerous operational roles at portfolio companies including Chief Scientific Officer of Senda Biosciences (now Sail Biomedicines) and Chief Operating Officer of Montai Therapeutics.

Prior to joining Flagship, Kyle served as Chief Operating Officer at LogicBio Therapeutics, where he was the second employee. During his time at LogicBio he held a diverse set of roles and responsibilities including program leadership and portfolio and product development strategy. He led regulatory engagements to open an IND for a first-in-class genome editing platform, supported multiple financing rounds including the company’s IPO, and facilitated business development engagements that led to multiple research and strategic collaborations. Prior to LogicBio, Kyle was an early employee at aTyr Pharma where he held various roles across discovery and clinical teams, serving as a program lead and supporting the intellectual property portfolio strategy.

Kyle earned a Ph.D. in macromolecular, cellular structure, and chemistry from the Scripps Research Institute under the mentorship of Professor Ben Cravatt and a B.S. in Biochemistry and Cell Biology with a minor in Economics from the University of California, San Diego. His undergraduate research on small molecule stabilizers of transthyretin in Professor Jeff Kelly’s group contributed to the discovery of Tafamidis, approved for patients with transthyretin amyloidosis.

Kyle is a co-author on more than 40 publications and patents.